Épisodes

  • Chronic Obesity Care: GLP-1s and Bariatric Surgery ft. Dr. Christine Ren-Fielding

    Chronic Obesity Care: GLP-1s and Bariatric Surgery ft. Dr. Christine Ren-Fielding
    Oct 20 2026
    In this episode of MD Newsline, Dr. Christine Ren-Fielding, Professor of Surgery at NYU Langone Health and Director of the NYU Weight Management Center, discusses the evolving, multimodal landscape of chronic obesity treatment. Drawing on over 25 years of clinical experience, Dr. Ren-Fielding contrasts the traditional perception of obesity as a personal failure with its reality as a lifelong, progressive metabolic condition. She explores how the body's physiological set point defends against weight loss, compares obesity management to chronic disease models such as cancer care, and outlines how surgical procedures, GLP-1 receptor agonists, and psychiatric support intersect to optimize long-term health outcomes and limb/metabolic preservation. Episode Highlights The Multidisciplinary Approach to Obesity Dr. Ren-Fielding outlines the parallel structure of medical and surgical care at the NYU Weight Management Center. She detail how board-certified obesity medicine physicians, bariatric surgeons, nurse practitioners, dietitians, and psychologists collaborate seamlessly to provide continuous care tailored to individual patient trajectories. Obesity as a Chronic Condition and Set Point Adaptation The discussion delves into metabolic adaptation and set point theory, explaining how human physiology actively defends against calorie restriction. Dr. Ren-Fielding highlights an anecdotal 75-pound weight-gain threshold where conservative measures like diet and exercise face biological resistance, drawing an analogy to cancer remission where multi-step interventions—such as surgery, chemotherapy, or pharmacotherapy—are needed over a patient's lifespan. Limitations of BMI and Population-Specific Guidelines Dr. Ren-Fielding evaluates body mass index (BMI) as a diagnostic tool, pointing out its inability to distinguish muscle mass in athletes or account for visceral fat distribution. She highlights how lower BMI cutoffs are critical for Asian populations due to heightened risk for metabolic syndrome, type 2 diabetes, hypertension, and metabolic dysfunction-associated steatohepatitis (MASH) at lower body weights. Red Flag Comorbidities for PCP Referral The episode outlines key medical indicators that primary care physicians (PCPs) should evaluate alongside BMI, including metabolic syndrome, severe sleep apnea, coronary artery disease, and fatty liver disease (MASH)—a leading cause of liver transplantation. Dr. Ren-Fielding advocates for earlier surgical referral in high-risk patients to prevent long-term organ damage. Integrating GLP-1 Receptor Agonists with Surgical Interventions Dr. Ren-Fielding shares her long-term experience with GLP-1 receptor agonists (including liraglutide, semaglutide, and tirzepatide), from early clinical trials treating weight recurrence after gastric bypass to current preventative and combination therapy uses. She addresses pre-surgical optimization, the impact of menopause and hysterectomy on weight gain, and how GLP-1s serve as a non-surgical step for post-operative plateaus. Evaluating Bariatric Options: Sleeve Gastrectomy, Gastric Bypass, and Lap-Band The conversation explores clinical selection criteria for procedures like sleeve gastrectomy, Roux-en-Y gastric bypass, and adjustable gastric banding (Lap-Band). Key factors include patient compliance, hiatal hernia presence, gastroesophageal reflux disease (GERD), pregnancy timelines, and patient preference. Dr. Ren-Fielding also discusses the ethical considerations surrounding aggressive intestinal bypasses like the duodenal switch and SADI-S due to severe risk of chronic protein deficiency and vitamin deficiencies. Defining Clinical Success Beyond the Scale Dr. Ren-Fielding redefines successful bariatric and medical outcomes, emphasizing that modest, sustained weight loss improves cardiovascular health, glycemic control, fertility, and overall quality of life far more effectively than volatile, extreme weight loss followed by recurrence. Key Takeaway Managing chronic obesity requires a long-term, multimodal strategy that moves beyond simplistic caloric models. By integrating advanced bariatric surgery, targeted GLP-1 receptor agonist therapies, behavioral healthcare, and personalized clinical decision-making, care teams can achieve sustainable remission, manage metabolic comorbidities, and dramatically improve patient quality of life. RESOURCES Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr. Christine Ren Fielding — https://nyulangone.org/doctors/1083626359/christine-ren-fielding LinkedIn — https://www.linkedin.com/in/christine-ren-fielding-md-facs-29472a12
    Afficher plus Afficher moins
    50 min
  • Healing Diabetic Wounds with Vasculogenic Fibroblasts

    Healing Diabetic Wounds with Vasculogenic Fibroblasts
    Oct 13 2026

    In this episode of MD Newsline, Dr. Kanhaiya Singh, Associate Professor at the University of Pittsburgh and researcher specializing in diabetic foot ulcers and ischemic wound healing, discusses groundbreaking discoveries in regenerative medicine that could reshape the treatment of chronic diabetic wounds. Dr. Singh explains how a newly identified population of vasculogenic fibroblasts supports blood vessel formation during wound healing and how diabetes disrupts this natural repair mechanism through epigenetic changes involving microRNA-200B (MIR-200B).

    He also explores the promise of tissue nanotransfection (TNT) technology, an innovative gene delivery platform designed to locally reprogram cells and restore healthy wound healing without traditional cell therapy. The conversation covers the science behind fibroblast state changes, AI-assisted biomarker discovery, and the path toward translating these findings into future clinical treatments for diabetic limb ischemia and chronic foot ulcers.

    Episode Highlights Understanding Vasculogenic Fibroblasts

    Dr. Singh introduces the discovery of vasculogenic fibroblasts, a specialized subset of fibroblasts that acquire blood vessel-forming properties while retaining their original fibroblast identity. Unlike traditional cell fate conversion, these cells undergo a state change, enabling them to support vascular repair without losing their normal wound-healing functions.

    Diabetes, Epigenetics, and Impaired Wound Healing

    The discussion explores how chronic hyperglycemia alters the wound microenvironment through DNA hypermethylation and epigenetic regulation. These changes suppress the formation of vasculogenic fibroblasts, reducing vascular regeneration and increasing the likelihood of chronic wounds and recurrent diabetic foot ulcers.

    The Role of MIR-200B

    Dr. Singh explains why microRNA-200B (MIR-200B) has emerged as a key molecular regulator of wound healing. Elevated MIR-200B levels in diabetes inhibit the development of vasculogenic fibroblasts, while targeted inhibition restores blood vessel formation, improves tissue perfusion, and accelerates wound healing in preclinical models.

    Tissue Nanotransfection: A New Regenerative Therapy

    The episode highlights tissue nanotransfection (TNT), an innovative silicon chip technology developed to deliver genetic therapies directly through the skin. By locally delivering anti-MIR-200B molecules, TNT reprograms resident fibroblasts to enhance vascular regeneration without the need for stem cell transplantation or donor cells.

    Why Cell Therapy Has Fallen Short

    Dr. Singh discusses the limitations of traditional cell therapies for diabetic limb ischemia, including poor cell survival, immune challenges, and unfavorable wound environments. He explains why in vivo cellular reprogramming through TNT may provide a more effective and clinically practical alternative.

    Biomarkers, Artificial Intelligence, and Precision Wound Care

    The conversation explores how single-cell RNA sequencing, spatial transcriptomics, and artificial intelligence are advancing the search for predictive biomarkers. Dr. Singh describes ongoing efforts within the Diabetic Foot Consortium to develop AI-driven tools capable of predicting whether diabetic wounds are likely to heal or become chronic.

    Translating Research into Clinical Practice

    Dr. Singh outlines the remaining steps before this technology reaches patients, including FDA approval of the tissue nanotransfection platform and clinical development of antisense oligonucleotide therapies. He anticipates that early clinical translation could begin within the next several years.

    Key Takeaway

    Dr. Singh emphasizes that improving diabetic wound healing requires more than simply closing wounds—it requires restoring healthy vascular biology. By combining epigenetics, regenerative medicine, tissue nanotransfection, and artificial intelligence, researchers are moving toward personalized therapies capable of preventing chronic wounds, improving limb preservation, and reducing diabetic complications.

    Resources

    Website: https://mdnewsline.com/

    Newsletter: https://mdnewsline.com/subscribe/

    Contact with Dr. Kanhaiya Singh: Here
    Afficher plus Afficher moins
    20 min
  • Beyond Autoantibodies: A New Approach to Predicting Type 1 Diabetes in Children

    Beyond Autoantibodies: A New Approach to Predicting Type 1 Diabetes in Children
    Sep 29 2026
    In this episode of MD Newsline, Dr. Brittany Bruggeman, a pediatric endocrinologist and physician-scientist at the University of Florida, discusses groundbreaking research presented at the American Diabetes Association (ADA) Scientific Sessions on the role of the exocrine pancreas in predicting Type 1 diabetes. Traditionally, researchers have focused on the insulin-producing islets, but Dr. Bruggemann explains why the much larger exocrine pancreas may hold valuable clues for identifying children at the highest risk of developing Type 1 diabetes years before symptoms appear. She explores findings from the TEDDY birth cohort, showing that changes in fecal elastase, a marker of exocrine pancreatic function, can be detected as early as four months of age in children who later develop Stage 3 Type 1 diabetes. Dr. Bruggemann also discusses how combining exocrine biomarkers with islet autoantibodies improves prediction accuracy, the clinical implications of exocrine pancreatic insufficiency, and how future advances in proteomics, imaging, AI, and multiomics may transform early diagnosis and disease prevention. Episode Highlights Why the Exocrine Pancreas Matters For decades, Type 1 diabetes research has centered on the insulin-producing islets. Dr. Bruggemann explains why researchers are now shifting attention to the exocrine pancreas, which makes up approximately 97% of the pancreas and may show measurable changes long before clinical diabetes develops. The TEDDY Study and Early Biomarkers Using more than 4,500 stool samples collected from over 250 children enrolled in the TEDDY study, researchers measured fecal elastase, a marker of exocrine pancreatic function, to determine whether early pancreatic changes could predict progression to Type 1 diabetes. Detecting Changes Before Autoimmunity One of the study's most surprising findings was that children who progressed rapidly to Stage 3 Type 1 diabetes already demonstrated differences in fecal elastase at an average age of four months—well before islet autoimmunity is thought to begin. This suggests that exocrine abnormalities may precede the autoimmune process itself. Improving Prediction by Combining Biomarkers Fecal elastase alone provided limited predictive power, but when combined with islet autoantibody status, researchers significantly improved their ability to predict progression to Stage 3 Type 1 diabetes within a one- to two-year timeframe—an important goal for clinical trials and disease-modifying therapies. Clinical Implications for Patients Dr. Bruggemann explains when clinicians should consider testing for exocrine pancreatic insufficiency, particularly in patients with established Type 1 diabetes who experience gastrointestinal symptoms such as bloating, cramping, or stool changes. She emphasizes that fecal elastase testing is inexpensive, reliable, and can identify a treatable condition that is often overlooked. Challenges and Limitations Although promising, fecal elastase testing requires stool collection, and sample quality can influence results. Dr. Bruggemann discusses current limitations and ongoing efforts to develop symptom-based screening tools that could help identify which patients should undergo testing. The Future of Type 1 Diabetes Prediction Looking ahead, Dr. Bruggemann envisions combining fecal elastase, serum biomarkers, genetic data, MRI imaging, proteomics, and artificial intelligence to build more accurate risk prediction models capable of identifying children most likely to develop Type 1 diabetes within the next few years. Key Takeaway Dr. Bruggemann's research suggests that the exocrine pancreas may provide previously overlooked biomarkers that improve the early prediction of Type 1 diabetes. While fecal elastase is not sufficient as a standalone predictor, combining it with autoantibodies, serum biomarkers, genetics, and advanced imaging could lead to earlier intervention, better clinical trial enrollment, and a deeper understanding of how Type 1 diabetes begins long before symptoms appear. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Brittany Bruggeman: Here
    Afficher plus Afficher moins
    20 min
  • Fatty Liver Disease in Type 2 Diabetes: The Hidden Role of Portal Insulin and Insulin Resistance

    Fatty Liver Disease in Type 2 Diabetes: The Hidden Role of Portal Insulin and Insulin Resistance
    Sep 15 2026
    In this episode of MD Newsline, Dr. Mohamed Abu-Farha, Principal Scientist at the Dasman Diabetes Institute in Kuwait, explores groundbreaking research into the relationship between portal insulin exposure, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease. Drawing from findings presented at ADA 2026, Dr. Abu-Farha explains how C-peptide measurements, ANGPTL8, and advanced metabolic phenotyping may improve clinicians' ability to identify patients at risk for liver fat accumulation without relying solely on imaging. He also discusses the future of predictive algorithms, GLP-1 therapies, insulin sensitizers, and precision medicine for diabetes care. Episode Highlights Understanding Portal Insulin and Liver Fat Dr. Abu-Farha explains why portal insulin concentration—rather than circulating insulin alone—may be a critical driver of liver fat accumulation. Because insulin travels directly from the pancreas to the liver through the portal vein, elevated portal insulin in insulin-resistant individuals may stimulate excessive fat storage in the liver. Why C-Peptide Matters Instead of measuring insulin alone, Dr. Abu-Farha highlights the importance of C-peptide as a more accurate reflection of pancreatic insulin production. Since insulin is partially cleared by the liver while C-peptide is not, C-peptide provides a better estimate of true portal insulin exposure. ANGPTL8 and Fatty Liver Development After more than a decade of research, Dr. Abu-Farha's team believes ANGPTL8 may serve as a biological link between hyperinsulinemia and hepatic fat accumulation. Their work shows strong associations between ANGPTL8, insulin resistance, triglyceride metabolism, and liver fat, opening new avenues for mechanistic and therapeutic research. Comparing Type 1 and Type 2 Diabetes Dr. Abu-Farha discusses why people with Type 1 diabetes generally develop less liver fat than those with early Type 2 diabetes. The difference, he explains, lies in the pattern of insulin delivery—subcutaneous insulin bypasses the portal circulation, whereas endogenous insulin production creates much higher portal insulin concentrations that may promote liver fat accumulation. Predicting Fatty Liver Without MRI One of the most promising aspects of Dr. Abu-Farha's research is the development of a mathematical prediction model capable of estimating liver fat using routine clinical measurements. Early findings show correlations exceeding 90% compared with imaging-based assessments, potentially making liver fat screening faster, less expensive, and more accessible. Practical Tools for Clinicians The research also demonstrates that readily available clinical measurements—including waist circumference and other metabolic indices—can provide strong estimates of fatty liver risk, helping physicians identify patients who may benefit from additional evaluation before advanced imaging is required. Rethinking Diabetes Therapy Dr. Abu-Farha discusses why reducing reliance on insulin, when clinically appropriate, may benefit some patients with Type 2 diabetes. Combining GLP-1 receptor agonists with insulin sensitizers could address the underlying causes of diabetes—obesity and insulin resistance—while potentially reducing long-term complications associated with excessive insulin exposure. The Future of AI and Precision Medicine Looking ahead, Dr. Abu-Farha envisions artificial intelligence and predictive algorithms becoming integrated into routine diabetes care. By combining metabolic biomarkers with simple clinical measurements, physicians could better estimate insulin resistance and fatty liver risk during everyday office visits. Next Steps in Research Future studies aim to directly test the portal insulin hypothesis in humans, including evaluating medications that suppress insulin production to determine their effect on liver fat accumulation. Dr. Abu-Farha believes these studies could provide definitive evidence supporting the proposed mechanism. Advances in Diabetes Treatment Dr. Abu-Farha concludes by highlighting the rapid evolution of diabetes therapies, including GLP-1 receptor agonists, amylin analogs, SGLT2 inhibitors, and emerging peptide-based treatments. He notes that developing safer and more effective insulin sensitizers remains an important unmet need in diabetes management. Key Takeaway Dr. Abu-Farha's research suggests that portal insulin exposure, insulin resistance, and ANGPTL8 signaling may play a central role in the development of MASLD (fatty liver disease). By combining routine clinical measurements, predictive algorithms, and a deeper understanding of disease biology, clinicians may soon be able to identify patients at risk earlier, reduce reliance on expensive imaging, and deliver more personalized diabetes care that targets the underlying mechanisms of metabolic disease. Resources Website: https://mdnewsline.com/ Newsletter: https://...
    Afficher plus Afficher moins
    21 min
  • Beyond GLP-1s: The Hidden Hunger Driving Obesity, Diabetes, and Emotional Eating

    Beyond GLP-1s: The Hidden Hunger Driving Obesity, Diabetes, and Emotional Eating
    Sep 1 2026
    In this episode of MD Newsline, Dr. Adrienne Youdim, an internist, obesity medicine specialist, and certified mind-body medicine physician, explores the often-overlooked emotional and psychological dimensions of obesity and diabetes care. Speaking from the American Diabetes Association (ADA) Scientific Sessions, Dr. Youdim explains why treating physical hunger alone is not enough, even in the era of GLP-1 medications. She discusses how stress, trauma, emotional regulation, and self-compassion influence hunger hormones, patient behaviors, and long-term health outcomes. Dr. Youdim also shares practical ways clinicians can incorporate mind-body medicine, breathing exercises, mindfulness, journaling, and compassionate communication alongside evidence-based obesity treatments to improve both physical and emotional well-being. Episode Highlights Understanding the "Hidden Hungers" Dr. Youdim introduces the concept of hidden hunger—the emotional, psychological, and spiritual needs that often drive eating behaviors beyond physical hunger. While GLP-1 medications effectively reduce appetite, they do not address underlying emotional stress, trauma, or unmet psychological needs that influence long-term health. How Stress Changes Hunger Hormones Stress affects the body's biology as much as its emotions. Dr. Youdim explains how acute stress and adverse childhood experiences increase ghrelin, the hormone responsible for stimulating hunger. This physiologic connection helps explain why chronic stress often leads to overeating and why addressing emotional health is an essential part of obesity treatment. Mind-Body Medicine as Clinical Care Mind-body practices such as breathing exercises, mindfulness meditation, yoga, expressive writing, and self-compassion training can reduce stress, improve emotional regulation, and encourage healthier behaviors. Dr. Youdim discusses how these evidence-based interventions can be easily integrated into routine clinical visits alongside medication therapy. Addressing Weight Stigma with Compassion Many patients arrive with previous experiences of weight bias and stigma that interfere with medical care. Dr. Youdim explains how brief breathing exercises and compassionate communication help establish trust, improve patient engagement, and create a safer clinical environment before discussing treatment plans. Diabetes, Food Anxiety, and Emotional Well-Being Patients living with diabetes often develop an intense focus on food choices, blood sugar, and body weight. While nutritional awareness is important, Dr. Youdim cautions that excessive attention to numbers may contribute to guilt, shame, self-stigma, and unhealthy relationships with food if not balanced with compassion. Finding the Right Balance When Discussing Weight Avoiding conversations about weight can be just as harmful as approaching them insensitively. Dr. Youdim encourages clinicians to engage patients in open, respectful conversations that acknowledge emotions, encourage self-compassion, and individualize discussions based on each patient's comfort level. GLP-1 Medications Within a Holistic Treatment Strategy Rather than replacing lifestyle change, GLP-1 medications reduce food noise and compulsive eating, allowing patients to better engage with nutrition, exercise, emotional healing, and behavioral change. Dr. Youdim views medications, behavioral therapy, and mind-body medicine as complementary components of comprehensive obesity care. Burnout, Leadership, and Hidden Hunger The same emotional deprivation affecting patients also contributes to clinician burnout and workplace challenges. Dr. Youdim explains how unmet emotional and relational needs can reduce resilience, impair decision-making, and negatively affect professional performance, making emotional wellness equally important for healthcare providers. Practical Tools for Patients and Clinicians Dr. Youdim recommends practical daily interventions including breathing exercises, mindfulness apps, journaling, body scans, and expressive writing. She emphasizes that physicians should first practice these techniques themselves before introducing them to patients, creating more authentic and effective care. Key Takeaway Dr. Adrienne Youdim emphasizes that the future of obesity and diabetes care extends far beyond medications alone. By recognizing hidden emotional hunger, addressing stress and trauma, integrating mind-body medicine, and combining these approaches with GLP-1 therapies and compassionate communication, clinicians can provide more comprehensive, patient-centered care that supports lasting physical and emotional health. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Learn more about Dr. Adrienne Youdim: Here
    Afficher plus Afficher moins
    24 min
  • Healing Diabetic Wounds with Vasculogenic Fibroblasts ft. Kanhaiya Singh, PhD

    Healing Diabetic Wounds with Vasculogenic Fibroblasts ft. Kanhaiya Singh, PhD
    Aug 28 2026
    In this episode of MD Newsline, Dr. Kanhaiya Singh, associate professor at the University of Pittsburgh, discusses his research into vasculogenic fibroblasts and their potential role in healing diabetic and ischemic wounds. He explains how a subset of fibroblasts can acquire vasculogenic properties while retaining their fibroblast identity, a process he describes as a state change rather than a fate change. Dr. Singh explores how diabetes and epigenetic changes can suppress the generation of vasculogenic fibroblasts, the role of miR-200b in regulating this process, and findings from lineage-tracing studies in animal models. He also discusses tissue nanotransfection as a potential approach for delivering anti-miR-200b to wound tissue and the remaining steps needed to move this research toward clinical applications. Episode Highlights: The Discovery of Vasculogenic Fibroblasts Dr. Singh explains how single-cell RNA sequencing and subsequent experiments revealed a fibroblast population with vasculogenic properties. Unlike a conventional cell-fate change, these cells retain fibroblast characteristics while acquiring endothelial-like functions, leading the researchers to describe them as vasculogenic fibroblasts. State Change Rather Than Cell Fate Change The discussion explores the distinction between a cell changing its fate and acquiring a new functional state. Dr. Singh explains that vasculogenic fibroblasts continue to maintain fibroblast properties while taking on vasculogenic functions, allowing specific fibroblast subsets to participate in vascular repair without completely becoming endothelial cells. How Diabetes Suppresses Vasculogenic Fibroblasts Dr. Singh discusses how the diabetic microenvironment can interfere with vasculogenic fibroblast generation. He describes the role of hyperglycemia, DNA methyltransferases, and DNA hypermethylation in suppressing the endothelial program needed for vasculogenic fibroblast production. The Role of miR-200b The conversation examines miR-200b, an epigenetic regulator that plays a central role in the emergence of vasculogenic fibroblasts. Dr. Singh explains how elevated miR-200b in diabetic fibroblasts may limit their vasculogenic capacity and how reducing miR-200b can promote the phenotype needed for vascular repair. Lineage Tracing and Vasculogenic Fibroblast Evidence Dr. Singh describes experiments using Col1a2-Cre mouse models and lineage tracing to investigate whether fibroblasts contribute directly to vascular structures. He discusses findings showing fibroblast lineage-labeled cells within CD31-positive blood vessels and explains how spatial transcriptomics is helping identify the fibroblast subsets involved in this process. Vasculogenic Fibroblasts in Chronic Wounds The discussion highlights how vasculogenic fibroblasts are diminished in chronic, diabetic, and ischemic wounds. Dr. Singh shares findings from mouse models suggesting that increasing the proportion of vasculogenic fibroblasts can improve wound closure and perfusion. Tissue Nanotransfection and miR-200b Targeting Dr. Singh explains how tissue nanotransfection uses a silicon chip with microneedles and a pulsatile electrical current to deliver genetic cargo into tissue. In this research, the approach is being used to deliver an antisense oligonucleotide targeting miR-200b with the goal of restoring vasculogenic activity within wound tissue. From Preclinical Research Toward Clinical Translation The interview explores what remains between the current research and potential clinical studies. Dr. Singh discusses ongoing work with human skin explants, the development of a proprietary wound-healing model, and efforts to make the tissue nanotransfection device FDA-compatible before advancing toward clinical applications. The Future of Epigenetic Biomarkers in Diabetic Wound Care Looking ahead, Dr. Singh highlights epigenetics as an important area of research, particularly the development of biomarkers that could help predict whether diabetic wounds will heal or recur. He also discusses the potential role of artificial intelligence in analyzing single-cell data and developing predictive biomarkers through the Diabetic Foot Consortium. Key Takeaway Vasculogenic fibroblasts represent a distinct fibroblast state that may contribute to vascular repair during wound healing. Dr. Singh's research suggests that diabetes can suppress this reparative capacity through epigenetic mechanisms involving miR-200b, while approaches such as tissue nanotransfection may offer a potential way to restore vasculogenic activity. Although this work remains in the preclinical and translational research stage, continued investigation into epigenetic biomarkers and tissue reprogramming could help advance new approaches to diabetic wound healing. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
    Afficher plus Afficher moins
    20 min
  • Beyond Blood Sugar: How Health Equity Can Transform Diabetes Outcomes

    Beyond Blood Sugar: How Health Equity Can Transform Diabetes Outcomes
    Aug 18 2026
    In this episode of MD Newsline, Dr. Sharita Golden, Professor of Endocrinology, Diabetes, and Metabolism at Johns Hopkins University School of Medicine, explores how achieving better diabetes outcomes requires addressing not only clinical care, but also health equity, social determinants of health, and system-level change. Drawing from decades of clinical practice, research, and advocacy, Dr. Golden explains how healthcare systems, public policy, culturally tailored interventions, and community partnerships can improve diabetes care for marginalized populations. She also discusses practical strategies clinicians can use to identify patient barriers, reduce disparities, and deliver more equitable, patient-centered care. Episode Highlights Rethinking Safe Glucose Management in the Hospital Dr. Golden reflects on her early experiences as a hospital endocrinologist, where she observed that inpatient systems often contributed to unsafe glucose management. She explains how standardized protocols, proactive insulin management, and evidence-based order sets can significantly improve patient safety and reduce complications such as hypoglycemia and hyperglycemia. Looking Beyond the Patient to the Healthcare System Health equity begins by asking what systemic barriers prevent patients and clinicians from achieving the best outcomes. Dr. Golden discusses how implementing standardized policies, clinical decision support, and quality improvement initiatives across multiple hospitals helped reduce disparities in diabetes care throughout an entire health system. Poverty as a Major Driver of Diabetes Disparities While racial and ethnic disparities remain important, Dr. Golden emphasizes that poverty and socioeconomic disadvantage often underlie poor diabetes outcomes across many communities. Limited access to healthcare, healthy food, safe environments for exercise, and transportation all contribute to persistent inequities in diabetes management. Why Social History Is Essential to Good Diabetes Care Dr. Golden encourages clinicians to ask open-ended questions that uncover the real-life challenges patients face. She shares a powerful example of a caregiver whose diabetes dramatically improved only after discussing the practical barriers preventing her from taking insulin consistently. Understanding a patient's daily life is often more valuable than simply adding medications. Culturally Tailored Care Improves Outcomes Successful diabetes interventions respect patients' cultural backgrounds and lifestyles. Dr. Golden explains how personalized nutrition counseling, community health workers, patient navigators, and delivering care in trusted community settings can substantially improve engagement and long-term diabetes control. Using Data to Drive Health Equity Collecting quality metrics is only the first step. Dr. Golden explains how stratifying data by geography, insurance status, and demographics enables health systems to identify underserved populations and develop targeted interventions such as telehealth programs, rural outreach clinics, and community-specific resources. The Role of Policy and Physician Advocacy Clinicians can extend their impact beyond the examination room by engaging with legislators and advocating for policies that improve access to care. Dr. Golden encourages healthcare professionals to share patient stories with policymakers to help shape legislation addressing diabetes disparities and broader public health challenges. Building Equity Through Community Partnerships Dr. Golden discusses how academic medical centers and community organizations can work together to expand successful diabetes care models. Investments in data infrastructure, quality improvement leaders, and community partnerships are essential for making equity-focused interventions sustainable across diverse healthcare settings. Moving Upstream to Address Social Determinants of Health Improving diabetes outcomes requires addressing the underlying social conditions affecting patients' lives. Dr. Golden illustrates how issues such as financial insecurity, housing instability, and utility access directly influence diabetes management, and how clinicians can connect patients with community resources while advocating for broader policy solutions. Expanding the Definition of Health Equity Dr. Golden concludes by emphasizing that diabetes inequities extend far beyond race and ethnicity. Rural communities, older adults, individuals living in poverty, and other marginalized populations all experience structural barriers to care. Addressing these shared challenges requires comprehensive solutions focused on improving access, affordability, and opportunity for every patient. Key Takeaway Dr. Golden demonstrates that better diabetes care requires more than prescribing medications—it demands addressing health equity, social determinants of health, system-wide quality improvement, culturally tailored interventions, and community partnerships. ...
    Afficher plus Afficher moins
    21 min
  • Treating Obesity Under Medicare: GLP-1 Access, Personalized Care, and System-Level Challenges

    Treating Obesity Under Medicare: GLP-1 Access, Personalized Care, and System-Level Challenges
    Aug 4 2026
    In this episode of MD Newsline, Dr. Michael Albert, obesity medicine specialist, internist, and Co-Founder of Accomplish Health, joins Dr. Spencer Nadolsky, board-certified obesity physician, family physician, lipidologist, and Founder of Vineyard, for an expert roundtable on the rapidly evolving landscape of Medicare coverage for obesity treatment. They discuss how GLP-1 receptor agonists, evolving CMS policies, and the proposed Medicare bridge model are changing obesity care for older adults while highlighting the importance of personalized medicine, long-term chronic disease management, clinical documentation, and multidisciplinary care. The conversation also explores barriers to medication access, prior authorization challenges, care infrastructure, patient education, and how success in obesity treatment should be measured beyond the number on the scale. Episode Highlights Medicare Coverage and Access to GLP-1 Medications Drs. Albert and Nadolsky explain why the greatest barrier to obesity treatment is often not identifying appropriate patients—but helping them obtain and maintain access to therapy. They discuss Medicare Part D coverage, prior authorization requirements, step therapy, and how insurance policies frequently determine clinical decision-making. Understanding the Medicare GLP-1 Bridge Program The discussion examines proposed Medicare eligibility criteria for GLP-1 therapies, including BMI thresholds, cardiovascular disease, chronic kidney disease, hypertension, and other qualifying conditions. The physicians explain how these criteria differ from traditional FDA labeling and what clinicians need to document for approval. Building Clinical Infrastructure for Success Effective obesity care requires more than prescribing medication. Dr. Albert shares how custom EHR workflows, automated documentation, digital intake tools, and streamlined prior authorization systems help practices deliver high-quality obesity care at scale while reducing administrative burden. Personalizing GLP-1 Therapy for Older Adults Older adults require individualized treatment strategies to minimize frailty, sarcopenia, dehydration, and gastrointestinal side effects. The physicians discuss dose titration, oral versus injectable formulations, nutritional monitoring, resistance exercise, and shared decision-making to safely optimize treatment. Setting Expectations for Long-Term Treatment Obesity is a chronic disease that often requires lifelong management. Drs. Albert and Nadolsky emphasize informed consent, discussing medication costs, potential loss of coverage, weight regain after discontinuation, and the importance of preparing patients for long-term therapy. Documentation That Improves Access The panel reviews best practices for documenting obesity severity, BMI, ICD-10 coding, and obesity-related comorbidities such as diabetes, hypertension, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease. Accurate documentation helps improve approval rates while supporting evidence-based care. Multidisciplinary Care and Care Coordination Managing obesity effectively requires collaboration among primary care physicians, obesity specialists, dietitians, cardiologists, endocrinologists, nephrologists, and bariatric surgeons. The physicians discuss referral pathways, closed-loop communication, digital health systems, and coordinated care models that improve patient outcomes. Measuring Success Beyond Weight Loss While weight reduction remains important, the physicians argue that true success should be measured by improvements in metabolic health, cardiovascular risk, mobility, functional independence, quality of life, medication reduction, and the ability to perform everyday activities—not simply achieving a target percentage of weight loss. Key Takeaway Drs. Albert and Nadolsky emphasize that obesity is a chronic disease, not simply a lifestyle issue, and effective treatment requires long-term access to GLP-1 medications, personalized care, thoughtful clinical infrastructure, multidisciplinary support, and patient-centered decision-making. As Medicare expands access to obesity therapies, success will depend not only on prescribing innovative medications but also on creating healthcare systems that deliver equitable, sustainable, and comprehensive obesity care while measuring outcomes by overall health, function, and quality of life rather than weight loss alone. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Featured Guests Dr. Michael Albert Co-Founder & Chief Medical Officer, Accomplish Health Obesity Medicine Specialist & Internist https://michaelalbertmd.com/ Dr. Spencer Nadolsky Founder, Vineyard Board-Certified Obesity Medicine Physician, Family Physician & Lipidologist https://drspencer.com/
    Afficher plus Afficher moins
    38 min